Clinical trials: Clostridium Difficile
Clostridioides Difficile Infection
Ursodeoxycholic Acid in C. Difficile Infection
The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid
- Trial name
- NCT05526807
- Testing
- Ursodeoxycholic acid
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Clostridium Difficile Infection
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial…
- Trial name
- NCT03466502
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Nevada, Reno
Clostridium Difficile Infection, Antibiotic Associated Diarrhea
Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea
Antibiotic-associated diarrhea (AAD) and particularly Clostridium difficile-Infection (CDI) are the most common causes of healthcare associated infectious diarrhea.
- Trial name
- NCT01972932
- Testing
- Bio K+® 2 capsules orally (or via nasogastric tube)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Bio-K Plus International Inc.
Biologic Markers, Clinical Markers
Personalized Needs in Clostridium Difficile Infections
To develop a score that can predict early from diagnosis of Clostridium difficile infection (CDI) the risk for relapse and of unfavorable outcome.
- Trial name
- SPECIFY (NCT02573571)
- Testing
- Development of biomarkers
- Where
- 12 sites in Greece
- Volunteers
- 150 people
- Sponsor
- University of Athens
Diarrhea Due to Clostridium Difficile
Host Immune Response to Clostridium Difficile Infection (ICD)
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C.
- Trial name
- ICD (NCT02440438)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Enterocolitis, Pseudomembranous Colitis
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
The purpose of this study is three fold: 1)To collect serum from patients with documented Clostridium difficile infection and test for the presence of antibody to C.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304408
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients.
- Trial name
- NCT05852587
- Testing
- Xylitol
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Brigham and Women's Hospital
Clostridium Difficile, Clostridium Difficile Infection
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
The host gastrointestinal microbiota is significantly influenced by antibiotic treatment which might favor Clostridium difficile infection (CDI), a frequent cause of community- and hospital-acquired, potentially life-threatening…
- Trial name
- TOCSIN (NCT01942447)
- Testing
- FMT, Vancomycin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Microbial Colonization
Effects of Intravenous (IV) Omadacycline on Gut Microbiome
Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact…
- Trial name
- NCT05515562
- Testing
- Omadacycline Injection
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection
Clostridioides difficile infection (CDI) is one of the most common hospital-acquired infectious diseases with a high mortality rate (6-30%).
- Trial name
- FILTRATE (NCT04960306)
- Testing
- Fecal filtrate transplantation, Conventional fecal microbiota transplantation
- Where
- Hungary
- Volunteers
- 238 people
- Sponsor
- University of Pecs
Clostridium Difficile Infection
IMT for Primary Clostridium Difficile Infection
This is a randomized controlled trial to compare the effect of a 10-day course of per oral metronidazole versus a one-time rectal instillation of an anaerobically cultivated human intestinal microbiota for the treatment of a…
- Trial name
- NCT02301000
- Testing
- Intestinal microbiota therapy, Metronidazole
- Where
- 7 sites in Norway
- Volunteers
- 21 people
- Sponsor
- Oslo University Hospital
Clostridium Difficile
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward.
- Trial name
- NCT03368105
- Testing
- Prevention of C. difficile infections using LP299v strain
- Volunteers
- 300 people
- Sponsor
- Medical University of Silesia
Diarrhea, Clostridium Difficile
Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient
Medical literature has dealt with various perspectives of probiotic therapy - prevention of antibiotic associated diarrhoea, Clostridium difficile, etc.
- Trial name
- NCT00506181
- Testing
- probiotic mixture
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Hadassah Medical Organization
Nosocomial Infections, Bloodstream Infection
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
The Oncoped 2006 study implements a multicenter prospective surveillance module for nosocomial infections in pediatric cancer patients.
- Conditions
- Nosocomial Infections, Bloodstream Infection, Invasive Aspergillosis
- Trial name
- Oncoped2006 (NCT00843804)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bonn
Clostridium Difficile Infection
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
The main hypothesis of the study is that Bezlotoxumab is well tolerated and effective in reducing the recurrence of ICD (Clostridium Difficile infection) in patients with a high risk of recurrence in the first episode of ICD.
- Trial name
- BEFORE (NCT04075422)
- Testing
- Bezlotoxumab Injection [Zinplava]
- Where
- 6 sites in Spain
- Volunteers
- 869 people
- Sponsor
- Fundacion SEIMC-GESIDA
Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea
Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.
- Trial name
- NCT06839209
- Testing
- Toxclean 1g
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- ABResearch S.r.l.
Clostridioides Difficile Infection
CMTS0929 for Clostridioides Difficile Infection
This is a prospective, open-label, single-arm study to explore the safety and the efficacy of CMTS0929 for patients with Clostridioides difficile infection (CDI).
- Trial name
- NCT06836427
- Testing
- CMTS0929
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Ulcerative Colitis, Inflammatory Bowel Diseases
Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population
This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale…
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Clostridioides Difficile Infection
- Trial name
- FRONTIER-UC (NCT07401680)
- Testing
- Lyophilized Fecal Microbiota Transplantation (LFMT)
- Where
- 2 sites in Canada
- Volunteers
- 85 people
- Sponsor
- University of Alberta
Clostridium Difficile Infection
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
The purpose of this study is to determine whether Fecal Microbiota Therapy (FMT) is effective vs. placebo in the prevention of C. difficile infection recurrence.
- Trial name
- MATCH (NCT03005379)
- Testing
- Fecal Microbiota Therapy (FMT)
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Clostridium Difficile, Colitis
The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers
The investigators hypothesize that development of symptoms characteristic of Clostridium difficile infection will be 2-3 times higher in asymptomatic carriers, compared to that of non carriers and expect to find risk factors for…
- Trial name
- NCT02063282
- Where
- Israel
- Volunteers
- 394 people
- Sponsor
- Amos Yinnon